- Q1 2024 Pharming Group NV Earnings Call TranscriptMay 08, 2024€1.05Earnings
- Q4 2023 Pharming Group NV Earnings Call TranscriptMar 14, 2024€1.05Earnings
- Q3 2023 Pharming Group NV Earnings Call TranscriptOct 26, 2023€1.14Earnings
- Q2 2023 Pharming Group NV Earnings Call TranscriptAug 03, 2023€1.08Earnings
- Pharming Group NV Annual Shareholders Meeting TranscriptMay 17, 2023
- Q1 2023 Pharming Group NV Earnings Call TranscriptMay 11, 2023€1.13Earnings
- Pharming Group NV Corporate Analyst Meeting TranscriptMar 27, 2023
- Q4 2022 Pharming Group NV Earnings Call TranscriptMar 16, 2023€1.07Earnings
- Q3 2022 Pharming Group NV Earnings Call TranscriptOct 27, 2022€1.26Earnings
- Q2 2022 Pharming Group NV Earnings Call TranscriptAug 04, 2022€0.761Earnings
- Q1 2022 Pharming Group NV Earnings Call TranscriptMay 12, 2022€0.8535Earnings
- Q4 2021 Pharming Group NV Earnings Call TranscriptMar 24, 2022€0.891Earnings
- Q4 2021 Pharming Group NV Earnings Call TranscriptMar 17, 2022€0.891Earnings
- Pharming Group NV Announces Leniolisib Results Call TranscriptFeb 03, 2022
- Q3 2021 Pharming Group NV Earnings Call TranscriptOct 28, 2021€0.7854Earnings
- Q2 2021 Pharming Group NV Earnings Call TranscriptAug 05, 2021€1Earnings
- Pharming Group NV and Orchard Therapeutics PLC Announce Collaboration to Develop and Commercialize Ex Vivo Autologous HSC Gene Therapy for Hereditary Angioedema Call TranscriptJul 01, 2021
- Pharming Group NV Annual Shareholders Meeting TranscriptMay 19, 2021
- Q1 2021 Pharming Group NV Earnings Call TranscriptMay 13, 2021€1.08Earnings
- Q4 2020 Pharming Group NV Earnings Call TranscriptMar 04, 2021€1.12Earnings
Q4 2020 Pharming Group NV Earnings Call Transcript
Good afternoon, ladies and gentlemen, and welcome to the full year results conference call -- full year results 2020 conference call.
Before I go into this, I would like to point you to the slide that says forward-looking statements as this presentation may contain some forward-looking statements, including statements about our beliefs and expectations that are based on our current plans, estimates and projections, as well as our expectations of external conditions and events.
And after doing this, I would like to have the honor to introduce my new colleague, Jeroen Wakkerman, our new CFO, who joined us from, what is it, 16th of November. So he's very fresh still to the company, and who's sitting here next to me. And I'm very pleased Jeroen joined us. And I would like to hand over to you, Jeroen, to provide us with the financial highlights.
Yes. Thank you very much, Sijmen. Maybe first a bit about why I joined Pharming at this
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)